Nachrichten zur Eli Lilly & Co. Aktie

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Eli Lilly is the leader in the GLP-1 space, but heres another GLP-1 stock and a medical device maker to…

Eli Lilly vs Novo Nordisk: The 1 Figure Investors Shouldnt Ignore

The market for obesity drugs may soon reach almost $100 billion.…

Stocks making the biggest moves premarket: Amazon, Reddit, Strategy, Molina, Strategy, Eli Lilly & more

These are the stocks posting the largest moves in premarket trading.…

Walmart’s $1T valuation: A bet on high-income shoppers

For years, the trillion-dollar club was an exclusive playground for tech giants, with their big spends and even bigger revenues.…

Hims & Hers Launches New Pill That Sends Shockwaves Across Weight-Loss Drugmakers Stocks

Hims & Hers Health, Eli Lilly, and Novo Nordisk shares all slid Thursday after Hims & Hers said it would…

Eli Lilly Just Delivered Fantastic News to Shareholders

The stock price has climbed in the triple digits over three years.…

Hims & Hers offers cheaper weight-loss pill in a shock to Novo

STORY: Shares of Novo Nordisk plunged again on Thursday after online telehealth firm Hims & Hers said it will offer…

This Healthcare Company Believes Its GLP-1 Pill Could Be "Next in Line" After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs.

Structure Therapeutics has a promising GLP-1 drug that is about to enter phase 3 trials.…

Why Eli Lilly Stock Just Dropped

Hims & Hers has a GLP-1 weight loss pill -- and its the cheapest one out there.…

Eli Lilly (LLY) im Pivotal-Point-Check: Pharma-Gigant knackt Billionen-Marke - 43 % Umsatzplus und Mega-Ausblick für 2026 lassen den Rivalen Novo-Nordisk alt aussehen!

Für das 4. Quartal 2025 wurde ein Umsatzsprung von 43 % auf 19,3 Mrd. USD gemeldet.   Die Verkäufe von Mounjaro und Zepbound verdoppeln sich nahezu und treiben…

Die Machtübernahme! Eli Lilly besteigt den Pharma-Thron und lässt Novo Nordisk alt aussehen!

Eli Lilly (LLY) ist nicht mehr nur ein Pharmaunternehmen, es ist eine unaufhaltsame Wachstumsmaschine. Während die Konkurrenz strauchelt, liefert der…

Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party?

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.…

Were raising our price target on Eli Lilly as the GLP-1 leader delivers a huge beat

Combined sales for the companys blockbuster GLP-1 drugs Zepbound and Mounjaro exceeded $1 billion, with each showing triple-digit growth.…

Eli Lillys GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026

The split in outlook underscores Lillys strong position in the obesity market, underpinned by more effective drugs and its direct-to-consumer…

Open Interest 2/4/2026

Get a jump start on the US trading day with Matt Miller and Dani Burger on "Bloomberg Open Interest." AI…

Eli Lilly Soared by 39% in 2025, but Heres Another Healthcare Stock to Buy in 2026

Eli Lilly is riding the GLP-1 gravy train, while this competitor is struggling to get on board.…

Eli Lilly (LLY) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool.DateFeb. 4, 2026 at 10 a.m. ETCall participantsChair and Chief Executive Officer — David RicksChief Financial…

Eli Lilly Says Weight Loss Pill On Track for 2Q Launch in US

Eli Lilly Chief Financial Officer Lucas Montarce says their weight loss pill is on track to launch in the US in…

Days after announcing Lehigh Valley investment, Eli Lilly predicting a blockbuster 2026

On Wednesday morning, the pharmaceutical giant with headquarters in Indianapolis, Ind. announced its financial results for the fourth quarter of…

Stocks making the biggest moves premarket: AMD, Uber, Eli Lilly, Super Micro, Chipotle, Enphase and more

These are the stocks posting the largest moves in premarket trading.…

Pharmahersteller Lilly glänzt mit Prognose - Aktie zieht vorbörslich kräftig an

INDIANAPOLIS (dpa-AFX) - Anders als Konkurrent Novo Nordisk rechnet der US-Pharmahersteller Lilly auch in…

Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar

Eli Lillys full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and…

Eli Lilly sees 2026 profit above estimates on weight?loss drug demand By Reuters

Eli Lilly sees 2026 profit above estimates on weight?loss drug demand…

Eli Lilly sees 2026 profit above estimates as demand for weight?loss drugs soars

Eli Lilly forecast 2026 profit above Wall Street estimates on Wednesday, betting on surging demand for its obesity drugs as…

Eli Lilly shares soar after Q4 beat, strong forecast on weight-loss drugs

Eli Lilly and Co (NYSE:LLY) shares surged 9.5% in Wednesday morning trading after the drugmaker posted fourth-quarter results that topped…

Citi flags bigger tests ahead after Novo Nordisk diabetes trial success

Bank says latest CagriSema results meet expectations, with investor focus shifting to head-to-head data against Eli Lilly’s tirzepatide. Novo Nordisk...…

Obesity market sales potential tightens as Novo and Lilly enter new era

The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade…

Cramer’s week ahead: Earnings from Eli Lilly, Alphabet and Amazon. Plus, jobs data

AMD, Alphabet and Amazon are among the heavyweight companies reporting earnings in the week ahead.…

Why the Market Dipped But Eli Lilly (LLY) Gained Today

In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a +1.27% move from the…

Futures: Risk-Off Shift For Market?

Google, AMD, Eli Lilly, Amazon and Palantir headline another big earnings week.…

Eli Lilly CEO says Medicare coverage of obesity drugs could change the game for upcoming pill launch

Lilly CEO Dave Ricks is confident in the ability of the companys pill to compete and is preparing for a…

Eli Lilly looks to sharpen its domestic supply edge by building another U.S. plant

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…

Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections

The plant will help make Lillys experimental drug called retatrutide, which has shown the highest weight loss seen to date…

Eli Lilly to build $3.5 billion Pennsylvania plant in US manufacturing push

Eli Lilly announced on Friday that it will build a pharmaceutical manufacturing facility in Pennsylvania, its fourth new site in…

FDA Decision on Eli Lillys Weight Loss Pill Delayed to Q2. Is This Bad News for the Stock?

The target action date for orforglipron is now April 10.…

Should You Buy Eli Lilly Before Feb. 4?

Is there another beat-and-raise in the pharmaceutical giants near future?…

Trump says Eli Lilly to build six US plants

U.S. President Donald Trump said on Thursday that he has spoken to the head of pharmaceutical company Eli Lilly and…

Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless

U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the Germany-based startup said on…

Eli Lilly partners with Seamless Therapeutics on gene editing treatments for hearing loss

Eli Lilly and Co (NYSE:LLY) announced that it has entered a strategic global research collaboration and licensing agreement with Seamless…

Exclusive: Novos Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows

Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine…

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks By Reuters

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks…

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major pharmaceutical…

Eli Lilly, Pfizer, AbbVie drugs targeted in third Medicare price talks By Investing.com

Eli Lilly, Pfizer, AbbVie drugs targeted in third Medicare price talks…

Where Will Eli Lilly Be in 10 Years?

Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage wont last forever.…

Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog

…

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

Eli Lilly (LLY) closed at $1 in the latest trading session, marking a -2.12% move from the prior day.…

Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?

Eli Lillys valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.…

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in…

Abivax CEO dismisses noise around rumored Eli Lilly bid

Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the French press that pharmaceutical giant Eli Lilly may…

Zacks Market Edge Highlights: TSLA, NVDA and LLY

Is the Magnificent 7 finished? NVDA shines while Tesla struggles and Eli Lilly surges, as Zacks Market Edge debates who…